Abstract 1826P
Background
Thrombosis is the second cause of death in oncologic patients, and antiangiogenic drugs increase thrombosis risk. Clinical trials report arterial thrombosis incidence of 3,8% and venous thrombosis 2,8%. In this study of actual clinical practice, we study the real incidence of thrombotic events in cancer patients treated with antiangiogenic drugs.
Methods
Clinical records of patients treated with antiangiogenic drugs in our hospital between 2011 and 2018 were reviewed. Treatments included bevacizumab, ramucirumab, pazopanib, sorafenib and sunitinib. Incidence of arterial and venous thrombosis was analyzed after a follow up period until june 2019. Other clinical factors and Khorana score were evaluated as predictive factors with a multivariate analysis.
Results
147 patients were included. 27 (18%) presented venous, arterial or both thrombosis. Khorana score at the beginning of antiangiogenic therapy was lower in patients who did not present thrombosis: Khorana score was 1 or 2 in 55% of patients who presented with thrombosis and was 0 in 52% of patients who did not present the event. Among the clinical factors analyzed, hypertension, dyslipidemia, diabetes, LDH over 600 U/L and treatment with corticosteroids were more frequent in the group of patients who developed thrombotic events.
Conclusions
Thrombotic events incidence in cancer patients is higher than reported in clinical trials, specially, when antiangiogenic drugs are used in systemic treatment. Other risk factors as hypertension, diabetes, dyslipidemia, steroids treatment or level of serum LDH should be evaluated in prospective trials to be included in decision making and improve sensitivity of thrombosis risk assesment scores.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.